ProAxsis secures c.£1.8mn investment

NetScientific PLC

15 April 2024

 

For release on RNS: 07.00, 15 April 2024

NetScientific plc

("NetScientific" or the "Company")

Respiratory disease diagnostics company ProAxsis secures c.£1.8 million investment

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that its portfolio company ProAxsis Limited (ProAxsis) has successfully closed a c.£1.8 million investment (Investment).

The Investment was led by the Company's wholly owned venture capital and corporate finance firm, EMV Capital, syndicated from a cohort of private investors. The Investment includes c.£211,000 from new investors, c.£36,000 from the exercise of warrants (Warrants) granted to existing investors in connection with convertible loan notes (CLNs), the conversion of the CLNs (and interest thereon) valued in total at c.£455,000, and the conversion of loans from NetScientific valued at c.£776,000. This additional funding is complemented by ongoing non-dilutive funding from, amongst other grants awarded, a recent c.£333,000 grant from Innovate UK.

The new shares issued in connection with the Investment (other than those resulting from the exercise of the Warrants), are preferred shares (Preferred Shares) with a liquidation preference multiple of 1.1 (Liquidation Preference). The new shares issued in connection with the exercise of the Warrants are ordinary shares. The two share classes rank pari passu save as regards the Liquidation Preference.

In addition to the Investment, ProAxsis has provided for up to a further £289,000 to be raised on the same terms as the existing new investors in the Preferred Shares (Follow-on Investment).

Following the Investment, the Company's direct stake in ProAxsis is 90.66 per cent, which equates to a post-investment fair value of c.£8.0 million, an increase of c.229 per cent. from the £3.5 million reported as at 30 September 2023. In addition, following the introduction of investors by EMV Capital, the NetScientific capital under advisory with ProAxsis is 8.81% of the fully diluted share capital.

The proceeds of the Investment (and any Follow-on Investment) will, inter alia, support ProAxsis in the development of its Patient Point of Care product range, and its working capital requirements, as well as its endeavours to attract strategic partners.

Dr Ilian Iliev, CEO of NetScientific, and Investor Director of ProAxsis said:

"We welcome this additional funding for ProAxsis. Complemented by the CLNs and Innovate UK grant, these investments demonstrate strong financial support as ProAxsis develops its offering to the respiratory disease market, whilst it explores options for a potential sale to a new strategic owner.

"EMV Capital securing this third party funding is a further example of our capital efficient investment model, allowing ProAxsis to grow without reliance upon the NetScientific balance sheet."

The person responsible for arranging the release of this announcement on behalf of the Company is Edward Hooper, General Counsel and Executive Director of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

-Ends-

NetScientific

NetScientific
Ilian Iliev, CEO	Via Belvedere Communications
Panmure Gordon (UK) Limited (NOMAD and Broker)
Emma Earl / Freddy Crossley / Will Goode / Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
Belvedere Communications John West / Llewellyn Angus / Lily Pearce	[phone]

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-efficient investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. 

Aside from the provision of assays, ProAxsis provides clinical services at its purpose-built laboratory facility in Belfast and supports pharmaceutical company-sponsored Phase I, II and III clinical trials.

www.proaxsis.com

 

END